Fair Value Measurements - Contingent Consideration (Details) - USD ($) |
3 Months Ended | 12 Months Ended | |||
---|---|---|---|---|---|
Jun. 30, 2023 |
Dec. 31, 2023 |
Jun. 21, 2023 |
Dec. 31, 2022 |
Feb. 25, 2019 |
|
Fair Value Measurements | |||||
Contingent consideration under RPAs, AAAs and CPPAs | $ 7,000,000 | $ 75,000 | |||
Changes in estimated fair value of contingent consideration | 75,000 | ||||
Bioasis | Royalty Purchase Agreement | |||||
Fair Value Measurements | |||||
Contingent consideration under RPAs, AAAs and CPPAs | $ 0 | 0 | $ 75,000 | $ 75,000 | |
Changes in estimated fair value of contingent consideration | $ (100,000) | ||||
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Regulatory milestones | |||||
Fair Value Measurements | |||||
Contingent consideration under RPAs, AAAs and CPPAs | 1,000,000.0 | $ 1,000,000.0 | |||
Changes in estimated fair value of contingent consideration | $ 0 |
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Changes in estimated fair value of contingent consideration. No definition available.
|
X | ||||||||||
- Definition Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|